Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 1;12(6):923-926.
doi: 10.21037/hbsn-23-476. Epub 2023 Nov 15.

Futibatinib: new targeted therapy in intrahepatic cholangiocarcinoma

Rita Khoury  1 , Nadine Khalife  2 , Rebecca Ibrahim  1 , Khalil Saleh  1
Affiliations
Editorial

Futibatinib: new targeted therapy in intrahepatic cholangiocarcinoma

Rita Khoury et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Futibatinib; RLY-4008; cholangiocarcinoma; infigratinib; pemigatinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-476/coif). The authors have no conflicts of interest to declare.

Comment on

  • Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
    Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Goyal L, et al. N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834. N Engl J Med. 2023. PMID: 36652354 Clinical Trial.

References

    1. Khoury R, Chahine C, Ibrahim R, et al. Futibatinib: paving the way to personalized medicine in intrahepatic cholangiocarcinoma. Future Oncol 2023;19:1161-3. 10.2217/fon-2023-0318 - DOI - PubMed
    1. Oh DY, Ruth He A, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid 2022. doi: .10.1056/EVIDoa2200015 - DOI - PubMed
    1. Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401:1853-65. 10.1016/S0140-6736(23)00727-4 - DOI - PubMed
    1. Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2014;59:1427-34. 10.1002/hep.26890 - DOI - PubMed
    1. Krook MA, Reeser JW, Ernst G, et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer 2021;124:880-92. 10.1038/s41416-020-01157-0 - DOI - PMC - PubMed